Abstract
Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 – because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known about TRAIL/TRAIL receptor expression, the molecular components of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Our laboratory was the first to report the possibility of TRAIL gene transfer therapy as an alternative method of using TRAIL as an antitumor therapy. As with recombinant proteins administered systemically, intratumoral TRAIL gene delivery also has limitations that can restrict its full potential. Translating the preclinical TRAIL studies into the clinic has started, with the hope that TRAIL will exhibit robust tumoricidal activity against human primary tumors in situ with minimal toxic side effects.
Keywords: TRAIL, apoptosis, tumor, adenovirus, immunotherapy
Current Gene Therapy
Title: TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Volume: 9 Issue: 1
Author(s): Thomas S. Griffith, Brittany Stokes, Tamara A. Kucaba, James K. Earel Jr., Rebecca L. VanOosten, Erik L. Brincks and Lyse A. Norian
Affiliation:
Keywords: TRAIL, apoptosis, tumor, adenovirus, immunotherapy
Abstract: Numerous studies have investigated the potential use of TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic since its discovery in 1995 – because TRAIL is a potent inducer of apoptosis in tumor cells but not in normal cells and tissues. Consequently, a great deal is known about TRAIL/TRAIL receptor expression, the molecular components of TRAIL receptor signaling, and methods of altering tumor cell sensitivity to TRAIL-induced apoptosis. Our laboratory was the first to report the possibility of TRAIL gene transfer therapy as an alternative method of using TRAIL as an antitumor therapy. As with recombinant proteins administered systemically, intratumoral TRAIL gene delivery also has limitations that can restrict its full potential. Translating the preclinical TRAIL studies into the clinic has started, with the hope that TRAIL will exhibit robust tumoricidal activity against human primary tumors in situ with minimal toxic side effects.
Export Options
About this article
Cite this article as:
Griffith S. Thomas, Stokes Brittany, Kucaba A. Tamara, Earel Jr. K. James, VanOosten L. Rebecca, Brincks L. Erik and Norian A. Lyse, TRAIL Gene Therapy: From Preclinical Development to Clinical Application, Current Gene Therapy 2009; 9 (1) . https://dx.doi.org/10.2174/156652309787354612
DOI https://dx.doi.org/10.2174/156652309787354612 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Anatomical Influences on Oncological Management
Current Cancer Therapy Reviews Disordered Interactome of Human Papillomavirus
Current Pharmaceutical Design Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry Current Trends in the Use of Cationic Polymer Assemblies for siRNA and Plasmid DNA Delivery
Pharmaceutical Nanotechnology Serum Levels of IL-6, TNF-α and IL-10 as Early Predictors of Mortality in Trauma Hemorrhagic Shock Patients
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Current Drug Metabolism Editorial (Thematic Issue: Emergence of the “New” Head and Neck Cancer Prevailing to Young, Nonsmoker, and Nondrinker - Oropharyngeal Cancer Associated with HPV Positive)
Current Cancer Therapy Reviews Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Melatonin Induces Apoptosis and Inhibits the Proliferation of Cancer Cells via Reactive Oxygen Species-mediated MAPK and mTOR Pathways
Clinical Cancer Drugs Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design